Literature DB >> 21571344

Statin use and risk of prostate cancer in a population of men who underwent biopsy.

Nelly Tan1, Eric A Klein, Jianbo Li, Ayman S Moussa, J Stephen Jones.   

Abstract

PURPOSE: We determined the association between statin use and prostate cancer in men who underwent prostate biopsy.
MATERIALS AND METHODS: We performed a retrospective cohort study of men who underwent prostate biopsy from 2000 to 2007 at Cleveland Clinic. Statin use was determined using outpatient pharmacy records, and clinical and pathological outcomes were obtained. Multivariate logistic regression analysis to determine the effects of statins (and duration of use) was performed after adjusting for age, body mass index, African-American race, number of cores taken and prostate volume.
RESULTS: We analyzed data from 4,204 patients, and we identified 3,182 (75.7%) not on statins and 1,022 on statins. Men diagnosed with prostate cancer on statins compared to those not taking statins were less likely to have digital rectal examination positivity (5.3% vs 8.9%, OR 0.7, p <0.01), Gleason score 7 or greater prostate cancer (61.4% vs 72.4%, OR 0.78, p = 0.02) and high volume prostate cancer (27.2 vs 31.4, p <0.01). Moreover statin users had lower prostate specific antigen compared to nonstatin users (5.13 vs 5.98, p = 0.03). Multivariate analysis adjusted risk ratios for prostate cancer diagnosis, high grade prostate cancer (Gleason score 7 or greater) and 3 or more cores positive in statin users were 0.92 (95% CI 0.85-0.98), 0.76 (95% CI 0.67-0.85) and 0.86 (95% CI 0.75-0.97) and only high grade prostate cancer persisted with length of use.
CONCLUSIONS: Statin use was associated with a decreased risk of prostate cancer, less frequent high grade prostate cancer and lower volume of prostate cancer, suggesting that statin use has a protective effect against prostate cancer.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571344     DOI: 10.1016/j.juro.2011.03.004

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications.

Authors:  Maria I Van Rompay; Keith R Solomon; J Curtis Nickel; Gayatri Ranganathan; Philip W Kantoff; John B McKinlay
Journal:  Eur J Cancer       Date:  2019-03-06       Impact factor: 9.162

Review 2.  Cholesterol and prostate cancer.

Authors:  Kristine Pelton; Michael R Freeman; Keith R Solomon
Journal:  Curr Opin Pharmacol       Date:  2012-07-21       Impact factor: 5.547

Review 3.  The current evidence on statin use and prostate cancer prevention: are we there yet?

Authors:  Mahmoud A Alfaqih; Emma H Allott; Robert J Hamilton; Michael R Freeman; Stephen J Freedland
Journal:  Nat Rev Urol       Date:  2016-10-25       Impact factor: 14.432

4.  Statin use and risk of prostate cancer in the prospective Osteoporotic Fractures in Men (MrOS) Study.

Authors:  June M Chan; Stephanie Litwack-Harrison; Scott R Bauer; Nicholas A Daniels; Timothy J Wilt; Jackilen Shannon; Douglas C Bauer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-08-09       Impact factor: 4.254

5.  Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy.

Authors:  Nicholas G Zaorsky; Mark K Buyyounouski; Tianyu Li; Eric M Horwitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-30       Impact factor: 7.038

6.  Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites.

Authors:  David G Menter; Victoria P Ramsauer; Sam Harirforoosh; Kanishka Chakraborty; Peiying Yang; Linda Hsi; Robert A Newman; Koyamangalath Krishnan
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

7.  Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines.

Authors:  M Olivan; M Rigau; E Colás; M Garcia; M Montes; T Sequeiros; L Regis; A Celma; J Planas; J Placer; J Reventós; I de Torres; A Doll; J Morote
Journal:  Biomed Res Int       Date:  2015-01-12       Impact factor: 3.411

8.  Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia.

Authors:  Sang Hun Lee; Tae Ju Park; Min Ho Bae; Sung Ho Choi; Young Sam Cho; Kwan Joong Joo; Chil Hun Kwon; Heung Jae Park
Journal:  Korean J Urol       Date:  2013-11-06

9.  Statin use and risk of prostate cancer: a meta-analysis of observational studies.

Authors:  Dipika Bansal; Krishna Undela; Sanjay D'Cruz; Fabrizio Schifano
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

10.  Genetic variations of the ADIPOQgene and risk of prostate cancer in Chinese Han men.

Authors:  Cheng-Yuan Gu; Qiao-Xin Li; Yao Zhu; Meng-Yun Wang; Ting-Yan Shi; Ya-Yun Yang; Jiu-Cun Wang; Li Jin; Qing-Yi Wei; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2014 Nov-Dec       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.